Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333010 | 0.91 | MEN1 (0.38) | KMT2AMEN1SMN1; SMN2PKMCNR1 | |
| SCHEMBL331635 | 0.91 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2PKMCNR1 | |
| SCHEMBL8295292 | 0.90 | KMT2A (0.38) | KMT2AMEN1SMN1; SMN2PKMCNR1 | |
| SCHEMBL331886 | 0.89 | MEN1 (0.39) | KMT2AMEN1SMN1; SMN2PKMCNR1 | |
| SCHEMBL331722 | 0.85 | MEN1 (0.39) | KMT2AMEN1SMN1; SMN2PKMCNR1 | |
| SCHEMBL10252097 | 0.84 | MEN1 (0.39) | KMT2AMEN1SMN1; SMN2PKMCNR1 | |
| SCHEMBL332743 | 0.82 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2CNR1CNR2 | |
| SCHEMBL5370483 | 0.82 | MEN1 (0.32) | KMT2AMEN1PKMMAPTALDH1A1 | |
| SCHEMBL331842 | 0.82 | MEN1 (0.35) | KMT2AMEN1SMN1; SMN2PKMCNR1 | |
| SCHEMBL27623414 | 0.81 | MEN1 (0.40) | KMT2AMEN1SMN1; SMN2PKMCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-1689752-B1 | PYRAZOLOPYRIMIDINES | PFIZER LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| EP-1689752-A1 | PYRAZOLOPYRIMIDINES | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| EP-1620437-A1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | KMT2A 4632/4885MEN1 702/4885SMN1; SMN2 2626/4885 |
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | KMT2A 4632/4885MEN1 702/4885SMN1; SMN2 2626/4885 |
| US-20070105877-A1 | Pyrazolopyrimidines | DPYD, CYP2D6, TPMT | KMT2A 3078/4885MEN1 929/4885SMN1; SMN2 1537/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | KMT2A 4632/4885MEN1 702/4885SMN1; SMN2 2626/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | KMT2A 4632/4885MEN1 702/4885SMN1; SMN2 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.